Identification of Graphic Markers of Neurocognitive Disorders (MG) — MG  

Alzheimer Disease Clinical Trial

Official title: Identification of Graphic Markers of Neurocognitive Disorders Such as Primary Progressive Aphasia (PPA) and Early-stage Alzheimer's Disease (AD) (MG)

Status Completed

Clinical Trial Summary

The diagnosis of neurocognitive disorders such as early Alzheimer's disease (AD) or primary progressive aphasia (PPA) is particularly difficult and constantly evolving, often leading to diagnostic erraticity. However, several studies have shown that graphic parameters are affected in people with moderate to severe Alzheimer's disease. The use of new technologies in the study and analysis of the abilities of people with neurodegenerative diseases is increasingly recommended. The use of a digital tablet with a stylus makes it possible to objectivize the kinematic parameters of writing (pressure, inclination, speed, jerk, time of writing task) and thus would allow a low-cost diffusion of this technology in particular by including it in already existing screening batteries.

The overall objective of the project is to characterize and compare the graphical markers of a writing task, either language-based (writing words, non-words, sentences) or non-language-based (drawing shapes), in patients with PPA, early-stage Alzheimer's disease (i.e., at the stage of minor neurocognitive disorders and major neurocognitive disorders at the beginning of the disease), and in people with no cognitive disorders.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Alzheimer Disease
• Aphasia
• Aphasia, Primary Progressive
• Frontotemporal Dementia
• Neurocognitive Disorders
• Pick Disease of the Brain
• Primary Progressive Aphasia

• NCT number: NCT05537688
• Study type: Observational
• Source: Centre integre universitaire de sante et de services sociaux du Centre-Sud-de-l'Île-de-Montréal
• Status: Completed
• Start date: June 27, 2022
• Completion date: August 27, 2023